These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32731769)

  • 1. Cardiovascular safety risks associated with gout treatments.
    Rosas G; Gaffo A; Rahn EJ; Saag KG
    Expert Opin Drug Saf; 2020 Sep; 19(9):1143-1154. PubMed ID: 32731769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of urate-lowering therapies: managing the risks to gain the benefits.
    Keenan RT
    Rheum Dis Clin North Am; 2012 Nov; 38(4):663-80. PubMed ID: 23137576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.
    Soskind R; Abazia DT; Bridgeman MB
    Expert Opin Pharmacother; 2017 Aug; 18(11):1115-1125. PubMed ID: 28658988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK; Singh JA
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
    Dalbeth N; Stamp L
    Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
    Li-Yu J; Clayburne G; Sieck M; Beutler A; Rull M; Eisner E; Schumacher HR
    J Rheumatol; 2001 Mar; 28(3):577-80. PubMed ID: 11296962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent approaches to gout drug discovery: an update.
    Otani N; Ouchi M; Kudo H; Tsuruoka S; Hisatome I; Anzai N
    Expert Opin Drug Discov; 2020 Aug; 15(8):943-954. PubMed ID: 32329387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunities for improving medication use and monitoring in gout.
    Singh JA; Hodges JS; Asch SM
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allopurinol: insights from studies of dose-response relationships.
    Day RO; Kannangara DR; Stocker SL; Carland JE; Williams KM; Graham GG
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):449-462. PubMed ID: 27927043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in pharmacotherapy for the treatment of gout.
    Robinson PC; Dalbeth N
    Expert Opin Pharmacother; 2015 Mar; 16(4):533-46. PubMed ID: 25547991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How common are side effects of treatment to prevent gout flares when starting allopurinol?
    Saul H; Deeney B; Swaithes L; Roddy E
    BMJ; 2024 Mar; 384():q514. PubMed ID: 38458626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
    Mackenzie IS; Ford I; Nuki G; Hallas J; Hawkey CJ; Webster J; Ralston SH; Walters M; Robertson M; De Caterina R; Findlay E; Perez-Ruiz F; McMurray JJV; MacDonald TM;
    Lancet; 2020 Nov; 396(10264):1745-1757. PubMed ID: 33181081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ANMCO statement: Uric acid and cardiovascular disease: evidence and therapeutic approach].
    Di Fusco SA; Castello L; Marino G; Flori M; Aquilani S; Riccio C; Nardi F; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
    G Ital Cardiol (Rome); 2023 Jun; 24(6):483-489. PubMed ID: 37227209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothyroidism on Colchimax revealed by restless legs syndrome.
    Bon E; Rolland Y; Laroche M; Cantagrel A; Mazières B
    Rev Rhum Engl Ed; 1996 Apr; 63(4):304. PubMed ID: 8738454
    [No Abstract]   [Full Text] [Related]  

  • 15. Gout and cardiovascular disease: crystallized confusion.
    Abeles AM; Pillinger MH
    Curr Opin Rheumatol; 2019 Mar; 31(2):118-124. PubMed ID: 30601229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
    Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
    J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
    Yamanaka H; Tamaki S; Ide Y; Kim H; Inoue K; Sugimoto M; Hidaka Y; Taniguchi A; Fujimori S; Yamamoto T
    Ann Rheum Dis; 2018 Feb; 77(2):270-276. PubMed ID: 29102957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of gout.
    Cohen MG
    Intern Med J; 2011 Jan; 41(1a):70-1. PubMed ID: 21265967
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluating appropriate use of prophylactic colchicine for gout flare prevention.
    George M; Pullman-Mooar S; Hussain F; Schumacher HR
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1258-62. PubMed ID: 24376081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.